Multiple endocrine neoplasia type 2

Familial Cancer

Volumn 4, Issue 1, 2005, Pages 25-36

  Peczkowska, Mariola ^a   Januszewicz, Andrzej ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Medullary thyroid carcinoma; MEN 2; Pheochromocytoma; RET

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AZELASTINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTEINE; DACARBAZINE; IMATINIB; MEMBRANE PROTEIN; METIROSINE; OCTREOTIDE; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SUCCINATE DEHYDROGENASE; VON HIPPEL LINDAU PROTEIN;

ADRENALECTOMY; AMYLOIDOSIS; AUTOSOMAL DOMINANT DISORDER; CALCITONIN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CELL HYPERPLASIA; CHROMAFFIN CELL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; GENE DUPLICATION; GENE LOCATION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIRSCHSPRUNG DISEASE; HUMAN; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PHENOTYPE; PHEOCHROMOCYTOMA; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTO ONCOGENE; REVIEW; SCINTISCANNING; THYMECTOMY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; ONCOGENE PROTEINS; PHEOCHROMOCYTOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 19944424474     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-005-0656-y     Document Type: Review

References (109)

1. CGP Mathew KS Chin DF Easton 1987 A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10 Nature 128 527 30
2. C Eng 1996 The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease N Engl J Med 335 943 51
3. G Opocher F Sciavi P Conton 2003 Clinical and genetic aspects of pheochromocytoma Horn Res 59(Suppl 1) 56 61
4. HPH Neumann DP Berger G Sigmund 1993 Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease N Engl J Med 329 1531 8
5. C Eng H Hampel A de la Chapelle 2000 Genetic testing for cancer predisposition Ann Rev Med 52 371 400
6. MS Cohen JE Phay C Albinson 2002 Gastrointestinal manifestations of multiple endocrine neoplasia type 2 Ann Surg 235 648 55
7. O Gimm 2001 Multiple endocrine neoplasia type 2: clinical aspects Front Horm Res 28 103 30
8. ML Brandi RF Gagel A Angeli 2001 Consensus. Guidelines for diagnosis and therapy of MEN type 1 and type 2 J Clin Endocrinol Metab 86 5658 71
9. S Casanova M Rosenberg-Bourgin D Farkas 1993 Pheochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases Clin Endocrinol 38 531 7
10. C Dotzenrath K Cupisti PE Goretzki 2001 Long-term biochemical results after operative treatment of primary hyperparathyroidism associated with multiple endocrine neoplasia type I and IIa: is a more or less extended operation essential Eur J Surg 167 173 8
11. I Schuffenecker M Virally-Monod R Brohet 1998 Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene J Clin Endocrinol Metab 83 487 91
12. J Zedenius C Larsson U Bergholm 1995 Mutation of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas J Clin Endocrinol Metab 80 3088 90
13. S Leboulleux JP Travagli B Caillou 2002 Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome. Influence on the stage on the clinical course Cancer 94 44 50
14. A Machens O Gimm R Hinze 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: Oncological features and biochemical properties J Clin Endocrinol Metab 86 1104 9
15. LM Mulligan C Eng CS Healey 1994 Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC Nat Genet 6 70 4
16. HPH Neumann S Hoegerle T Manz 2002 How many pathways to pheochromocytoma Sem Nephrol 22 89 99
17. LM Mulligan DJ Marsh BG Robinson 1995 Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET mutation Consortium J Intern Med 238 343 6
18. C Eng D Clayton I Schuffenecker 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium analysis JAMA 276 1575 9
19. C Eng DP Smith LM Mulligan 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours Human Mol Genet 3 2 237 41
20. LM Mulligan JBJ Kwok CS Healey 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 363 458 60
21. AM Alvares Da Silva RM Maciel MR Dias Da Silva 2003 A novel germ-line point mutation in RET exon 8 (gly(533)cys) in a large kindred with familial medullary thyroid carcinoma J Clin Endocrinol Metab 88 5438 43
22. RA Decker ML Peacock P Watson 1998 Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation Human Mol Genet 7 1 129 34
23. M Kambouris CE Jackson GL Feldman 1996 Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations Hum Mut 8 64 70
24. JE Blaugrund MM Johns YJ Eby 1994 RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer Hum Mol Genet 3 1895 7
25. K Frank-Raue W Höppner A Frilling 1996 Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype J Clin Endocrinol Metab 81 1780 3
26. I Klein O Erik V Homolya 2001 Molecular genetic diagnosis program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndrome in Hungary J Endocrinol 170 661 6
27. P Igaz A Patocs K Racz 2002 Occurrence of pheochromocytoma in a MEN 2A family with codon 609 mutation of the RET proto-oncogene J Clin Endocrinol Metab 87 2994
28. H Donis-Keller S Dou D Chi 1994 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 3 237 41
29. RM Landsvater RP Jansen RM Hofstra 1996 Mutation analysis of the RET proto-oncogene in Duth families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A Hum Genet 97 11 4
30. J Oriola C Paramo I Halperin 1998 Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma Am J Med Genet 78 271 3
31. M Nishikawa Y Murakumo T Imai 2003 Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung disease Eur J Hum Genet 11 364 8
32. DJ Marsh BG Robinson S Andrew 1994 A rapid screening method for the detection of mutations in RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families Genomics 23 477 9
33. B Pasini R Rossi MR Ambrosio 2002 RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease Surgery 131 372 81
34. T Attie A Pelet P Edery 1995 Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease Hum Mol Genet 4 1381 6
35. C Eng LM Mulligan 1997 Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease Hum Mutat 9 97 109
36. I Schuffenecker M Billaud A Calender 1994 RET proto-oncogene mutations in French MEN 2A and FMTC families Hum Mol Genet 3 1939 43
37. Y Kitamura PJ Goodfellow K Shimizu 1997 Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC Oncogene 14 3103 6
38. U Verga L Fugazzola S Cambiaghi 2003 Frequent association between MEN 2A and cutaneous lichen amyloidosis Clin Endocrinol 59 156 61
39. R McMahon LM Mulligan CS Healey 1994 Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2A families Hum Mol Genet 3 643 6
40. M Seri I Celli N Betsos 1997 A cys 634gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis Clin Genet 51 86 90
41. C Eng DP Smith LM Mulligan 1995 A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC Oncogene 10 509 13
42. G Antinolo I Marcos RM Fernandez 2002 A novel germline point mutation, c2304->T, in codon 768 of the RET proto-oncogene in a patient with medullar thyroid carcinoma Am J Med Genet 110 85 7
43. A Miyauchi F Matsuzuka K Hirai 2002 Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations World J Surg 26 1023 8
44. W Mashek R Pichler R Rieger 2002 A new indentified germline mutation of the RET proto-oncogene responsible for familial medullary carcinoma in co-existence with a hyperfunctioning autonomous nodule Clin Endocrinol 56 823
45. I Berndt M Reuter B Saller 1998 A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A J Clin Endocrinol Metab 83 770 4
46. O Gimm BE Niederle T Weber 2002 RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome Surgery 132 952 9
47. A Bolino I Schuffenecker Y Luo 1995 RET mutations in exons 13 and 14 of FMTC patients Oncogene 10 2415 9
48. O Nilsson LE Tisell S Jansson 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation JAMA 281 1587
49. M Fink A Wienhusel B Niederle OA Haas 1996 Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. 'Study Group Multiple Endocrine Neoplasia Austria (SMENA)' Int J Cancer 69 312 6
50. R Demeester J Parma P Cochaux 2001 A rare variant, I852M, of the RET proto-oncogene in a patient with medullary thyroid carcinoma at age 20 years Hum Mutat 17 354
51. O Gimm DJ Marsh SD Andrew 1997 Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation J Clin Endocrinol Metab 82 3902 4
52. RM Hofsra O Fatturoso L Quadro 1997 A novel point mutation in the intracellular domain of the ret protoncogene in a family with medullary thyroid carcinoma J Clin Endocrinol Metab 82 4176 8
53. C Jimenez MA Habra SC Huang 2004 Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation J Clin Endocrinol Metab 89 4142 5
54. C Jimenez GT Dang PN Schultz 2004 A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma J Clin Endocrinol Metab 89 3521 6
55. KM Carlson S Dou D Chi 1994 Single missense mutation in tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B Proc Natl Acad Sci USA 91 1579 83
56. Y Kitamura N Scavarda Jr SA Wells 1995 Two maternally derived missense mutations in the tyrosine kinase domain of the RET protooncogene in a patient with de novo MEN 2B Hum Mol Genet 4 1987 8
57. P Pigny C Bauters JL Wemeau 1999 A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma J Clin Endocrinol Metab 84 1700 4
58. W Hoppner MM Ritter 1997 A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A HumMol Genet 6 587 90
59. Hoppner W, Dralle H, Brabant G. Duplication of 9 base pairs in the critical cysteine rich domain of the RET proto-oncogene causes of multiple endocrine neoplasia type 2A. Hum Mutat 1998; (Suppl. 1): S128-S30
60. A Tessitore AA Sinisi MC Pasquali 1999 A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene J Clin Endocrinol Metab 84 3522 7
61. AB Nunes MCL Ezabella AC Pereira 2002 A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma J Clin Endocrinol Metab 87 5658 61
62. A Miyauchi H Futami N Hai 1999 Two Germline missense mutations at codon 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without 918 mutation Jpn J Cancer Res 90 1 5
63. L Kasprzak S Nolet L Gaboury 2001 Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET J Med Genet 38 784 7
64. FH Menko RB van der Luijt IAJ de Valk 2002 Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918 J Clin Endocrinol Metab 87 393 7
65. DK Bartsch C Hasse C Schug 2000 A RET double mutation in the germline of the kindred with FMTC Exp Clin Endocrinol Diabetes 108 128 32
66. ER Maher C Eng 2003 The pressure rises: update on genetics of phaeochromocytoma Human Mol Genet 11 2347 54
67. L Yip GJ Cote SE Shapiro 2003 Multiple endocrine neoplasia type 2. Evaluation of the genotype-phenotype relationship Arch Surg 138 409 16
68. MK Punales H Graf JL Gross AL Maia 2003 RET codon 634 mutations in multiple endocrine neoplasia type 2A - variable clinical features and clinical outcome J Clin Endocrinol Metab 88 6 2644 9
69. HPH Neumann C Eng LM Mulligan 1995 Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II JAMA 274 1149 51
70. P Niccoli-Sire A Murat V Rohmer 2001 Familial medullary thyroid carcinoma with noncysteine RET mutations: phenotype-genotype relationship in a large series of patients J Clin Endocrinol Metab 86 8 3746 53
71. HJ Karga MK Karayianni DA Linos 1998 Germ line mutation analysis in families with multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma Eur J Endocrinol 139 410 5
72. DJ Marsh LM Mulligan C Eng 1997 RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma Horm Res 47 4-6 168 78
73. I Schuffenecker N Ginet D Goldgar 1997 Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma Am J Hum Genet 60 233 7
74. KE Shannon O Gimm R Hinze 1999 Germline V804M mutation in the RET proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life J Endocr Genet 1 39 45
75. C Segouffin-Cariou M Billaud 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway J Biol Chem 275 5 3568 76
76. F Lombardo E Baudin E Chiefari 2002 Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804 J Clin Endocrinol Metab 87 1674 80
77. O Nilsson LE Tisell S Jansson 1999 Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation JAMA 281 17 1587 88
78. A Machens P Niccoli-Sire J Hoegel 2003 Early malignant progression of hereditary medullary thyroid carcinoma N Engl J Med 349 1517 27
79. J Cote RF Gagel 2003 Lessons learned from management of a rare genetic cancer N Engl J Med 349 1566 68
80. M Robledo L Gil M Pollan 2003 Polymorphism G691S/S904S of RET asgenetic modifiers of MEN 2A Cancer Res 63 1814 19
81. FJ Pomares JM Rodriguez F Nicolas 2002 Presurgical assessment of the tumor burden of familial medullary thyroid carcinoma by calcitonin testing J Am Coll Surg 195 630 4
82. MS Cohen JF Moley 2003 Surgical treatment of medullary thyroid carcinoma J Int Med 253 616 26
83. AEF Viera MP Mello LLK Elias 2002 Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A Horm Metab Res 34 202 6
84. JB Fleming JE Lee M Bouvet 1999 Surgical strategy for treatment of medullary thyroid carcinoma Ann Surg 230 697 707
85. E Kebebew PHG Ituarte AE Siperstein 2000 Medullary thyroid carcinoma. Clinical characteristic, treatment, prognostic factors, and a comparison of staging systems Cancer 88 1139 48
86. G Szinnai C Meier P Komminoth UW Zumsteg 2003 Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis Pediatrics 111 132 9
87. GE Sanso HM Domene MC Garcia Rudaz 2002 Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children Cancer 94 323 30
88. O Gimm J Ukkat H Dralle 1998 Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary carcinoma World J Surg 22 562 8
89. JMR Gonzales MD Balsalobre F Pomares 2002 Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center J Am Coll Surg 195 159 66
90. T de Kahraman JWB Groot C Rouwe 2002 Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a EJSO 29 331 5
91. Sherman S, Angelos P, Ball DWB et al. Medullary carcinoma in 'Thyroid Carcinoma Practice Guidelines in Oncology' version 1.2004. National Comprehensive Cancer Network 1-5
92. S Simon M Pavel J Hensen 2002 Multiple endocrine neoplasia type 2A syndrome: surgical management J Pediatr Surg 37 897 900
93. H Dralle O Gimm D Simon 1998 Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience World J Surg 22 744 51
94. HPH Neumann B Bausch SR McWhinney 2002 Germ-line mutations in nonsyndromic pheochromocytoma N Engl J Med 346 1459 66
95. NM Kaplan 1998 Pheochromocytoma (with a preface about incidental adrenal masses) NM Kaplan Clinical Hypertension. Williams and Wilkins Baltimore, MD 345 64
96. E Modigliani HM Vasen K Raue 1995 Pheochromocytoma in multiple endocrine neoplasia type 2: European study J Intern Med. 238 363 7
97. HP Neumann 2002 Imaging vs. biochemical testing for pheochromocytoma JAMA 288 314 5
98. AM Sawka R Jaeschke RJ Singh WF Young 2003 A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines J Clin Endocrinol Metab 88 2 553 8
99. G Eisenhofer 2003 Editorial: Biochemical diagnosis of pheochromocytoma - is it time to switch to plasma-free metanephrines J Clin Endocrinol Metab 88 2 550 2
100. G Eisenhofer JW Lenders WM Linehan 1999 Plasma normetanephrine and metanephrines for pheochromocytoma in von Hippel - Lindau disease and multiple endocrine neoplasia type 2 N Engl J Med 340 1872 9
101. W Raber W Raffesberg M Bischof 2000 Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma Arch Intern Med 160 2957 63
102. V Gardet B Gatta G Simonnet 2001 Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma J Hypertens 19 1029 35
103. RE Goldstein JA O'Neill GW Holcomb 1999 Clinical experience over 48 years with pheochromocytoma Ann Surg 229 755 66
104. 18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38 6 8
105. S Hoegerle E Nitzsche C Altehoefer 2003 Pheochromocytomas: detection with 18F DOPA whole-body PET - initial results Radiology 222 507 12
106. JE Lee SA Curley RF Gagel 1996 Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma Surgery 120 1064 71
107. HPH Neumann BU Bender M Reincke 1999 Adrenal-sparing surgery for phaeochromocytoma Br J Surg 86 94 7
108. M Lamarre-Cliche AP Gimenez-Roqueplo E Billaud 2002 Effects of slow-release octerotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma Clin Endocrinol 57 5 629 34
109. A Hartley D Spooner AM Brunt 2001 Management of malignant pheochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands Clin Oncol 13 361 6